Want to see SLXN full AI Analyst Report?
Top Page
Silexion Therapeutics
(NASDAQ:SLXN)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.14
â–¼(-62.22% Downside)
Action:Upgraded
Date:10/26/26
The score is held down primarily by weak financial performance (no revenue, continued losses, high cash burn, and a very thin equity base with high leverage). Technicals also remain bearish with the stock trading below all major moving averages and negative MACD. Corporate events provide some offset via clinical trial progress and scientific updates, but Nasdaq compliance and dilution-related financing/restructuring risks materially temper the upside.
Positive Factors
Clinical advancement
Initiating a global Phase 2/3 study moves SIL204 from development planning into active clinical execution. The randomized design, multi-site expansion, and dual-route dosing could create meaningful value if the therapy demonstrates safety and efficacy in a high-need cancer indication.
Negative Factors
Pre-revenue losses
Silexion has not yet established commercial revenue and continues to report substantial losses, so its financial profile depends on successful clinical development rather than operating cash generation. Profitability remains unproven, and earnings volatility limits confidence in durable internal funding capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical advancement
Initiating a global Phase 2/3 study moves SIL204 from development planning into active clinical execution. The randomized design, multi-site expansion, and dual-route dosing could create meaningful value if the therapy demonstrates safety and efficacy in a high-need cancer indication.
Read all positive factors
Silexion Therapeutics (SLXN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.16M
Dividend YieldN/A
Average Volume (3M)15.97M
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue GrowthN/A
EPS Growth98.10%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-56.54
Shares Outstanding14,473,292
10 Day Avg. Volume1,620,521
30 Day Avg. Volume15,972,612
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-100.53
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-48.45
Revenue Forecast (FY)N/A
Silexion Therapeutics Business Overview & Revenue Model
Company Description
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The c...
Silexion Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -14.07M | -11.88M | -16.48M | -5.02M | -3.32M | -755.00K |
| Net Income | -13.96M | -11.91M | -16.44M | -4.94M | -3.21M | -755.22K |
Balance Sheet | ||||||
| Total Assets | 4.25M | 7.21M | 2.86M | 5.26M | 9.33M | 115.41M |
| Cash, Cash Equivalents and Short-Term Investments | 2.23M | 5.99M | 1.19M | 4.59M | 8.26M | 38.94K |
| Total Debt | 1.41M | 468.00K | 4.49M | 171.00K | 271.00K | 0.00 |
| Total Liabilities | 4.20M | 4.61M | 6.85M | 17.31M | 16.41M | 508.92K |
| Stockholders Equity | 44.00K | 2.60M | -3.99M | -15.48M | -10.66M | 114.91M |
Cash Flow | ||||||
| Free Cash Flow | -12.43M | -10.83M | -8.42M | -4.54M | -3.38M | -1.41M |
| Operating Cash Flow | -12.43M | -10.82M | -8.40M | -4.53M | -3.33M | -1.41M |
| Investing Cash Flow | -8.00K | -14.00K | -22.00K | 573.00K | -524.00K | 0.00 |
| Financing Cash Flow | 11.23M | 15.64M | 5.10M | 522.00K | 2.75M | 116.40M |
Silexion Therapeutics Technical Analysis
Negative
0.36
Price Trends
0.29
Negative
1.26
Negative
6.79
Negative
Market Momentum
-0.07
Negative
31.80
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLXN, the sentiment is Negative. The current price of 0.36 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.29, and below the 200-day MA of 6.79, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 31.80 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLXN.
Silexion Therapeutics Risk Analysis
Silexion Therapeutics disclosed 56 risk factors in its most recent earnings report. Silexion Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Silexion Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $29.29M | -0.03 | -58.08% | ― | ― | 86.74% | |
47 Neutral | $17.37M | -0.08 | 204.18% | ― | ― | 35.03% | |
43 Neutral | $2.97M | -0.87 | -34.23% | ― | ― | 85.52% | |
42 Neutral | $2.16M | >-0.01 | -563.11% | ― | ― | 98.10% | |
41 Neutral | $337.23K | -0.01 | 455.31% | ― | -74.05% | 73.08% |
* Healthcare Sector Average
SLXN
Silexion Therapeutics
0.14
-33.00
-99.57%
MBIO
Mustang Bio
0.39
-1.06
-72.97%
LYRA
Lyra Therapeutics
0.19
-5.57
-96.70%
RNAZ
TransCode Therapeutics
1.73
-9.47
-84.55%
AEON
AEON Biopharma
0.29
-0.56
-65.41%
Silexion Therapeutics Corporate Events
Business Operations and StrategyShareholder MeetingsStock Split
Silexion Therapeutics Shareholders Approve Major Capital Restructuring
Positive
Oct 26, 2026
At an extraordinary general meeting originally held on October 19, 2026 and reconvened on October 26, 2026, Silexion Therapeutics shareholders approved an amendment to the company’s memorandum of association to significantly increase its aut...
Business Operations and StrategyProduct-Related Announcements
Silexion Therapeutics Begins Global SIL204 Pancreatic Cancer Trial
Positive
Sep 30, 2026
On September 30, 2026, Silexion Therapeutics announced that the first patient worldwide was successfully dosed in its global Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center in Israel. The study c...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Silexion Therapeutics Announces Warrant Inducement Financing Deal
Positive
Sep 29, 2026
On September 28, 2026, Silexion Therapeutics entered into an inducement offer with holders of 3,216,928 existing Series E warrants, cutting the exercise price from $0.65 to $0.2603 per share in exchange for immediate cash exercise and the issuance...
Business Operations and StrategyProduct-Related Announcements
Silexion Highlights Positive Translational Data for RNAi Oncology
Positive
Sep 28, 2026
On September 28, 2026, Silexion Therapeutics reported positive translational preclinical data showing that its lead RNAi candidate SIL204 uses naturally circulating serum lipoproteins to enter KRAS-driven cancer cells and achieve potent, dose-depe...
Shareholder MeetingsStock Split
Silexion Therapeutics Shareholders Reject Capital Structure Changes
Negative
Sep 25, 2026
On September 23, 2026, Silexion Therapeutics Corp reconvened its extraordinary general meeting after two prior adjournments due to lack of quorum, with shareholders holding about 36.8% of outstanding ordinary shares present. Under its articles of ...
Delistings and Listing ChangesRegulatory Filings and Compliance
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice
Negative
Sep 25, 2026
On September 25, 2026, Silexion Therapeutics received a notice from Nasdaq’s Listing Qualifications Staff that its ordinary shares had closed below the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a bid pr...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal
Negative
Aug 21, 2026
On August 18, 2026, Silexion Therapeutics received a delisting notice from the Nasdaq Listing Qualifications Department for failing to meet the minimum $2.5 million shareholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), after...
Financial DisclosuresRegulatory Filings and ComplianceShareholder MeetingsStock Split
Silexion Therapeutics Executes Reverse Share Split Amid Strain
Negative
Aug 13, 2026
On May 28, 2026, Silexion Therapeutics executed a 1-for-10 reverse share split of its issued, outstanding and authorized but unissued ordinary shares, following shareholder approval at extraordinary general meetings held on April 28 and May 5, 202...
Business Operations and StrategyPrivate Placements and Financing
Silexion Therapeutics Closes Public Offering and Strengthens Equity
Positive
Aug 13, 2026
On August 11, 2026, Silexion Therapeutics priced a $2.5 million public offering of ordinary shares and warrants, and on August 13, 2026, it closed the deal, issuing 2,028,619 shares, 1,817,542 pre-funded warrants and 3,846,161 Series E warrants at...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Silexion Updates SIL204 Clinical and Regulatory Roadmap
Positive
Aug 10, 2026
On August 10, 2026, Silexion Therapeutics published an updated corporate presentation outlining a revised clinical and regulatory timeline for SIL204, its second-generation lead siRNA candidate for KRAS-driven cancers, following initiation of a Ph...
Business Operations and StrategyProduct-Related Announcements
Silexion unveils key SIL204 KRAS preclinical findings
Positive
Aug 4, 2026
On August 4, 2026, Silexion Therapeutics reported new preclinical data showing that its KRAS-targeting siRNA candidate SIL204 induces a multi-mechanism immune-sensitizing effect in KRAS-mutant pancreatic and non-small cell lung cancer cell lines. ...
Executive/Board ChangesRegulatory Filings and Compliance
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance
Positive
Aug 3, 2026
On July 30, 2026, Silexion Therapeutics director Professor Amnon Peled notified the board that he would resign from the board and all its committees, including the audit committee, effective August 1, 2026, citing personal reasons and no disagreem...
Executive/Board Changes
Silexion Therapeutics Announces Board Member Resignation
Neutral
Jul 31, 2026
On July 30, 2026, Silexion Therapeutics Corp disclosed that Professor Amnon Peled had informed the Board of Directors of his decision to resign as a board member for personal reasons. His resignation was scheduled to take effect on August 1, 2026 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.